BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation ...
Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the ...
Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, ...
Enable Injections closed a $215 million Series C financing in January 2022 led by Magnetar Capital, including Sanofi and multiple additional new institutional investors. Enable received significant ...
Delcath Systems announces publication of subgroup analyses of phase 3 FOCUS study of Melphalan/Hepatic Delivery System in patients with unresectable metastatic uveal melanoma Queensbury, New York ...
Enable Injections announced today that it received a commitment from Sanofi for a $30 million investment to drive growth.
Vera Therapeutics stock rose on FDA acceptance of atacicept BLA for priority review in IgAN, a potential multi-billion dollar ...
Subcutaneous anifrolumab significantly reduces disease activity in patients with moderate to severe systemic lupus erythematosus.
To derive blood pressure, the device measures the time-of-flight between ultrasound echoes reflected from the anterior and ...
CINCINNATI ( Cincinnati Business Courier) - Enable Injections, one of Cincinnati's best-funded startups with hundreds of ...
The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback